Table 1 Baseline characteristics ( n = 359 )
Characteristic | Low dose (n = 60) | Intermediate dose (n = 77) | High dose (n = 222) | |
|---|---|---|---|---|
Gender | Females | 27 (45.0%) | 30 (50.6%) | 98 (44.1%) |
Males | 33 (55.0%) | 47 (49.4%) | 124 (55.9%) | |
Age [y] | Median | 51.1 | 55.4 | 59.0 |
Range | 18.1-77.0 | 21.9-80.5 | 20.5-81.1 | |
Disease Duration [y] | Median | 1.9 | 1.4 | 1.9 |
Range | 0.1-25.8 | 0.1-18.6 | 0.1-27.5 | |
Pretreatment | Surgery | 35 (58.3%) | 36 (46.8%) | 125 (56.3%) |
Chemotherapy | 14 (23.3%) | 16 (20.8%) | 38 (17.1%) | |
Radiation | 21 (35.0%) | 31 (40.3%) | 72 (32.4%) | |
Extent | Single Metastasis | 3 (5.0%) | 11 (14.3%) | 28 (12.6%) |
Liver Metastases | 48 (80.0%) | 62 (80.5%) | 189 (85.1%) | |
Bone Metastases | 16 (26.7%) | 17 (22.1%) | 47 (21.2%) | |
Creatinine [μmol/L] | Median | 63 | 71 | 69 |
Range | 22-258 | 26-138 | 33-369 | |
Tumor Uptake | Score 1 | 5 (8.3%) | 10 (13.0%) | 18 (8.1%) |
Score 2 | 6 (10.0%) | 8 (10.4%) | 11 (5.0%) | |
Score 3 | 49 (81.7%) | 59 (76.6%) | 193 (87.0%) | |
Kidney Uptake | Score 0 | 2 (3.3%) | 3 (3.9%) | 11 (5.0%) |
Score 1 | 4 (6.6%) | 8 (10.4%) | 20 (0.2%) | |
Score 2 | 12 (20.0%) | 10 (13.0%) | 52 (23.4%) | |
Score 3 | 42 (70.0%) | 55 (71.4%) | 137 (61.7%) | |
Histology | Carcinoid | 19 (31.7%) | 38 (49.4%) | 106 (47.7%) |
PNET | 15 (25.0%) | 21 (17.3%) | 64 (28.8%) | |
Rare NET | 17 (28.3%) | 9 (11.7%) | 26 (11.7%) | |
Unknown Primary | 9 (15.0%) | 9 (11.7%) | 26 (11.7%) |